Replies to post #147644 on Biotech Values

[Kadaicher1]

LLY, Just like to point out in a small 84 week open label extension trial with Prana's original drug PBT1(clioquinol), they halted decline in that same pre specified cognitive end point, MMSE, with more advanced paients.
http://www.pranabio.com/downloads/Media%20Releases/2004%2012%20Oct%20Open%20Label%20Ext%20Study%20of%20PBT%201%20Reinforces%20Positive%20Results.pdf

PBT2, an MPAC designed for better BBB penetration than clioquinol, has never been out to that point. The current 12 month IMAGINE trial should do better than the above. Apart from the supposedly more potent drug, this trial is in prodromal and very mild Alzheimer's. All PET positive for AB plaques.